IL6 and temporal arteritis: In patients who are at increased risk for adverse effects related to glucocorticoids, guideline therapy recommends adding tocilizumab, an IL-6 inhibitor that works by decreasing the formation of acute phase reactants which trigger inflammation in diseases like GCA.